Prihlásiť sa Zaregistrujte sa zadarmo

Beta spoločnosti Cotinga Pharmaceuticals

Aká je hodnota metriky Beta spoločnosti Cotinga Pharmaceuticals?

Hodnota metriky Beta spoločnosti Cotinga Pharmaceuticals, Inc. je 1.62

Aká je definícia metriky Beta?



BETA koeficient vyjadruje či je akcia volatilnejšia ako celkový trh. Beta nižšie ako 1 značí, že akcia je menej volatilná ako trh a beta vyššie ako 1 značí, že akcia je volatilnejšia. Volatilita sa miera pomocou kolísavosti ceny akcie.

Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.

Beta spoločností v sektore Health Care sektor na TSXV v porovnaní so spoločnosťou Cotinga Pharmaceuticals

Čomu sa venuje spoločnosť Cotinga Pharmaceuticals?

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.

Firmy s metrikou beta podobnou spoločnosti Cotinga Pharmaceuticals